with salt of mean Total cholesterol: -0.2 supplementation differences mmol/L (CI: -0.65, 0.25) (providing (from WHO) 50mmol HDL: -0.05 mmol/L sodium/day) 0.15) (from WHO) 2. Moderately reduced salt diet with placebo Key features for bias assessment of randomised trials Citation Method of Allocation Blinding Loss to Use of Ceasing study Reporting Funding source randomisation concealment early for benefit all where outcome required results Meland et Unclear risk Low risk Participants: 0% loss to Not required No (low risk) Yes (low University of al. (2009) (method of (randomisation Low risk follow-up (low (low risk) risk) Bergen, randomisation not list concealed risk) Solstrandsfondet Providers: Low stated) from (low risk) risk investigators) Outcome assessors: unclear risk Summary table
with salt supplementation (providing 50mmol sodium/day) 2. Moderately reduced salt diet with placebo of mean differences Total cholesterol: -0.2 mmol/L (CI: -0.65, 0.25) (from WHO) HDL: -0.05 mmol/L 0.15) (from WHO) Key features for bias assessment of randomised trials Citation Method of randomisation Allocation concealment Blinding Loss to Use of where required Ceasing study early for benefit Reporting all outcome results Funding source Meland et al. (2009) Unclear risk (method of randomisation not stated) Low risk (randomisation list concealed from investigators) Participants: Low risk Providers: Low risk Outcome assessors: unclear risk 0% loss to follow-up (low risk) Not required (low risk) No (low risk) Yes (low risk) University of Bergen, Solstrandsfondet (low risk) Summary table